Table 2.
Summary of co-clinical trials.
| Author | Year1 | Origin2 | Cases3 | Strain4 | Site5 | Animals6 |
|---|---|---|---|---|---|---|
| Stebbing [37] | 2014 | Sarcoma | 16 | Nude | sc11 | Unknown |
| Kopetz [48] | 2015 | CRC7 | 1 | NSG | sc11 | 1 |
| Owonikoko [64] | 2016 | SCLC8 | 5 | Nude | sc11 | 3 to 6 |
| Frankel [76] | 2017 | Melanoma | 4 | NSG | sc11 | 7 to 10 |
| Kim [78] | 2017 | LSCC9 | 5 | NOG/Nude | sc11 | 6 to 7 |
| Pauli [81] | 2017 | Solid tumor | 19 | Nude | sc11 | 5 |
| Campbell [90] | 2018 | OCSCC10 | 1 | NSG | sc11 | 7 |
| Harris [98] | 2018 | Melanoma | 3 | Nude | sc11 | 8 to 10 |
| Vargas [15] | 2018 | Clear cell adenocarcinoma | 1 | NSG | sc11 | 3 |
1 Publication year. 2 Origin of cancer for PDX models. 3 Number of PDX models. 4 Mouse strain. 5 Implantation site. 6 Number of animals per each treatment group. 7 Colorectal cancer. 8 Small cell lung cancer. 9 Lung squamous cell carcinoma. 10 Oral cavity squamous cell carcinoma. 11 Subcutaneously implantation.